Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4647049
Max Phase: Preclinical
Molecular Formula: C57H62N10O8S
Molecular Weight: 1047.25
Molecule Type: Unknown
Associated Items:
ID: ALA4647049
Max Phase: Preclinical
Molecular Formula: C57H62N10O8S
Molecular Weight: 1047.25
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](C(C)C)N2Cc3ccccc3C2=O)c(OCCCOCCC(=O)N2CCC(n3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)c1
Standard InChI: InChI=1S/C57H62N10O8S/c1-35(2)51(66-31-40-10-7-8-13-45(40)56(66)71)57(72)65-32-42(68)29-46(65)55(70)59-30-39-15-14-38(52-36(3)62-34-76-52)28-47(39)74-26-9-25-73-27-22-48(69)64-23-20-41(21-24-64)67-54-49(53(58)60-33-61-54)50(63-67)37-16-18-44(19-17-37)75-43-11-5-4-6-12-43/h4-8,10-19,28,33-35,41-42,46,51,68H,9,20-27,29-32H2,1-3H3,(H,59,70)(H2,58,60,61)/t42-,46+,51+/m1/s1
Standard InChI Key: YAKBRBQHMAONAH-QSDOZQHJSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1047.25 | Molecular Weight (Monoisotopic): 1046.4473 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Jaime-Figueroa S, Buhimschi AD, Toure M, Hines J, Crews CM.. (2020) Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties., 30 (3): [PMID:31879210] [10.1016/j.bmcl.2019.126877] |
Source(1):